1. Home
  2. PMTS vs FULC Comparison

PMTS vs FULC Comparison

Compare PMTS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CPI Card Group Inc.

PMTS

CPI Card Group Inc.

HOLD

Current Price

$28.24

Market Cap

332.4M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.85

Market Cap

285.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMTS
FULC
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
332.4M
285.4M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
PMTS
FULC
Price
$28.24
$3.85
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$27.67
$16.38
AVG Volume (30 Days)
112.9K
1.6M
Earning Date
05-05-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$312,189,000.00
N/A
Revenue This Year
$9.95
N/A
Revenue Next Year
$10.02
N/A
P/E Ratio
$83.46
N/A
Revenue Growth
12.27
N/A
52 Week Low
$10.81
$2.83
52 Week High
$31.25
$15.74

Technical Indicators

Market Signals
Indicator
PMTS
FULC
Relative Strength Index (RSI) 60.69 51.07
Support Level $27.00 $3.44
Resistance Level $31.25 $3.96
Average True Range (ATR) 1.04 0.09
MACD -0.30 0.00
Stochastic Oscillator 55.25 48.72

Price Performance

Historical Comparison
PMTS
FULC

About PMTS CPI Card Group Inc.

CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: